Study of 750,000 pregnancies reveals a surprising twist about Ozempic and Wegovy
Researchers found the elevated preterm-birth risk was confined to women using semaglutide or liraglutide for diabetes, not weight loss.
4 Articles
4 Articles
Weight-loss Ozempic-type drugs were not linked to higher preterm birth risk near conception in a Danish study—but diabetes users had higher odds
A Danish registry study found no added preterm birth risk among women using semaglutide or liraglutide for weight loss near conception, but higher odds among diabetes users.
Study of 750,000 pregnancies reveals a surprising twist about Ozempic and Wegovy
A study of more than 750,000 pregnancies found that early exposure to Ozempic, Wegovy, and similar drugs was not linked to increased pregnancy complications when used for weight loss, but was associated with a higher risk of premature birth when prescribed for diabetes. The surprising difference suggests that diabetes itself may be driving the risk, although researchers caution that the drugs' safety during pregnancy remains uncertain.
A study has found that even if women used Wigovi or Ozempic without knowing they were pregnant, the risk of premature birth or other pregnancy complications did not significantly increase if the goal was weight loss. Conversely, the risk of premature birth was found to increase in women prescribed the same class of drugs for diabetes treatment. According to Science Daily on the 13th (local time), researchers at the Department of Obstetrics and…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium






